Health CarePharmaceuticals and Biotechnology
  • Price (USD)389.71
  • Today's Change5.35 / 1.39%
  • Shares traded43.27k
  • 1 Year change-3.43%
  • Beta0.8631
Data delayed at least 15 minutes, as of Jan 20 2022 14:38 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

  • Revenue in USD (TTM)4.28bn
  • Net income in USD906.00m
  • Incorporated2000
  • Employees7.80k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Cognex Corporation1.02bn295.69m12.17bn2.06k41.848.1538.3111.971.651.655.668.440.49483.907.26494,719.2014.3915.2615.5416.4274.1074.7029.0828.723.58--0.0048.9811.7712.48-13.5810.35-14.2616.47
Bio-Rad Laboratories, Inc.2.98bn6.66bn17.94bn8.00k2.711.172.646.02220.42220.4298.67512.480.18642.047.27372,451.9041.6519.8143.9021.9057.8955.00223.4752.392.89--0.00080.0010.124.74116.43102.03-2.45--
Waters Corporation2.74bn694.92m19.80bn7.40k29.1067.2223.947.2411.1511.1543.914.830.94433.155.33369,740.9023.9814.1131.5816.4858.8458.6325.4023.981.8927.180.84530.00-1.712.98-11.442.1510.85--
PerkinElmer, Inc.5.06bn1.13bn22.31bn14.00k17.593.2115.604.4110.0510.0544.7155.140.46473.765.79361,246.4010.425.7811.706.7657.9250.1922.4112.111.4021.850.42319.2431.1812.44215.9230.9922.390.00
Avantor Inc7.27bn465.60m22.64bn12.40k47.257.3026.873.110.78630.786312.306.740.65686.146.54586,241.904.79--5.39--33.52--7.29--2.064.650.5765--5.85--115.52------
Fortive Corp4.60bn1.66bn25.90bn17.00k15.612.7813.085.634.634.4513.0925.980.28583.234.51270,464.7010.626.1713.027.5258.9453.3937.1715.520.6687--0.23112.051.54-5.59594.739.87-8.82--
AMETEK, Inc.5.24bn929.40m32.12bn16.50k34.744.9026.576.134.004.0022.5428.350.47415.176.83317,679.808.418.599.749.9734.7336.5617.7315.880.809815.700.288116.31-11.992.701.298.111.4414.87
Keysight Technologies Inc4.94bn894.00m33.03bn14.30k37.738.6727.836.684.784.7826.4220.800.65882.447.37345,524.5011.927.6814.189.2562.1158.1718.0911.732.3414.450.32130.0017.0611.1142.5821.6913.84--
Mettler-Toledo International Inc.3.62bn754.41m33.77bn16.50k46.05212.1539.289.3331.9031.90153.046.921.214.446.43219,313.7025.2620.0835.8627.7758.6857.7720.8517.620.863423.840.91410.002.545.197.4211.312.31--
Agilent Technologies Inc6.32bn1.21bn42.41bn17.00k35.667.8727.706.713.943.9420.5717.840.62163.765.72371,705.9011.9010.0514.1111.9953.9253.9519.1517.371.7418.220.336222.5218.368.5068.2921.246.3411.36
Roper Technologies Inc5.77bn1.12bn46.67bn18.40k42.044.1227.818.0910.5310.5354.28107.530.24369.796.15313,630.404.386.404.927.2166.9963.0918.0020.680.76926.370.423417.172.999.06-46.286.416.1615.44
Emerson Electric Co.18.24bn2.30bn56.74bn86.70k24.805.7217.223.113.833.8330.3016.590.76635.375.40210,334.509.789.7213.1213.5841.4742.1312.7612.031.0221.130.401859.588.644.6617.207.695.381.23
Illumina, Inc.4.28bn906.00m60.08bn7.80k63.355.7053.7314.046.076.0728.7767.470.3813.228.01548,717.908.0712.558.8715.3369.3068.6621.1724.212.24--0.13740.00-8.587.85-34.537.285.74--
Data as of Jan 20 2022. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

42.18%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Sep 202120.63m13.20%
The Vanguard Group, Inc.as of 30 Sep 202111.24m7.19%
BlackRock Fund Advisorsas of 30 Sep 20217.10m4.54%
Edgewood Management LLCas of 30 Sep 20216.91m4.42%
SSgA Funds Management, Inc.as of 30 Sep 20215.95m3.81%
Wellington Management Co. LLPas of 30 Sep 20213.27m2.09%
Loomis, Sayles & Co. LPas of 30 Sep 20213.20m2.05%
Geode Capital Management LLCas of 30 Sep 20212.62m1.68%
Polen Capital Management LLCas of 30 Sep 20212.54m1.62%
Walter Scott & Partners Ltd.as of 30 Sep 20212.48m1.59%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.